Literature DB >> 20056182

Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Bharat K R Chaganty1, Ashlesh K Murthy, Shankar J Evani, Weidang Li, M Neal Guentzel, James P Chambers, Guangming Zhong, Bernard P Arulanandam.   

Abstract

We have shown previously that vaccination with recombinant chlamydial protease-like activity factor (rCPAF) plus interleukin-12 as an adjuvant induces robust protective immunity against primary genital Chlamydia muridarum challenge in mice. Since CPAF is a protease, we compared the effects of enzymatically active and inactive (heat denatured) rCPAF to determine whether proteolytic activity is expendable for the induction of protective immunity against chlamydial challenge. Active, but not inactive, rCPAF immunization induced high levels of anti-active CPAF antibody, whereas both induced robust splenic CPAF-specific IFN-gamma production. Vaccination with active or inactive rCPAF induced enhanced vaginal chlamydial clearance as early as day 6 with complete resolution of infection by day 18, compared to day 30 in mock-vaccinated and challenged animals. Importantly, significant and comparable reductions in oviduct pathology were observed in active and inactive rCPAF-vaccinated mice compared to mock-vaccinated animals. Thus, rCPAF induced anti-chlamydial immunity is largely independent of enzymatic activity and secondary or higher order protein conformation. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056182      PMCID: PMC2846592          DOI: 10.1016/j.vaccine.2009.12.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Cleavage of host keratin 8 by a Chlamydia-secreted protease.

Authors:  Feng Dong; Heng Su; Yanqing Huang; Youmin Zhong; Guangming Zhong
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

2.  Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge.

Authors:  S Pal; I Theodor; E M Peterson; L M de la Maza
Journal:  Vaccine       Date:  1997-04       Impact factor: 3.641

3.  Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.

Authors:  B P Arulanandam; M O'Toole; D W Metzger
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

4.  Human antibody responses to a Chlamydia-secreted protease factor.

Authors:  Jyotika Sharma; Anthony M Bosnic; Jeanna M Piper; Guangming Zhong
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

Review 5.  Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms.

Authors:  Kathleen A Kelly
Journal:  Int Rev Immunol       Date:  2003 Jan-Feb       Impact factor: 5.311

6.  Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery.

Authors:  B P Arulanandam; D W Metzger
Journal:  Vaccine       Date:  1999-01-21       Impact factor: 3.641

Review 7.  Chlamydial protease-like activity factor--insights into immunity and vaccine development.

Authors:  Ashlesh K Murthy; M Neal Guentzel; Guangming Zhong; Bernard P Arulanandam
Journal:  J Reprod Immunol       Date:  2009-10-23       Impact factor: 4.054

8.  Intramolecular dimerization is required for the chlamydia-secreted protease CPAF to degrade host transcriptional factors.

Authors:  Feng Dong; Jyotika Sharma; Yanming Xiao; Youmin Zhong; Guangming Zhong
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

9.  Cleavage-dependent activation of a chlamydia-secreted protease.

Authors:  Feng Dong; Mustak Pirbhai; Youmin Zhong; Guangming Zhong
Journal:  Mol Microbiol       Date:  2004-06       Impact factor: 3.501

10.  Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors.

Authors:  G Zhong; P Fan; H Ji; F Dong; Y Huang
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  14 in total

1.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

Review 2.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

3.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

4.  Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Caixia Shen; Peter Andersen; Robert C Brunham
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

5.  Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.

Authors:  Weidang Li; Pareesha Gudipaty; Chuxi Li; Kyle K Henderson; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Immunol Cell Biol       Date:  2018-08-23       Impact factor: 5.126

Review 6.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

7.  Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge.

Authors:  Ashlesh K Murthy; Weidang Li; M Neal Guentzel; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2011-02-05       Impact factor: 3.641

8.  A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.

Authors:  Weidang Li; Ashlesh K Murthy; Gopala Krishna Lanka; Senthilnath L Chetty; Jieh-Juen Yu; James P Chambers; Guangming Zhong; Thomas G Forsthuber; M Neal Guentzel; Bernard P Arulanandam
Journal:  Vaccine       Date:  2013-10-01       Impact factor: 3.641

9.  TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models.

Authors:  Felipe V Pereira; Amanda C L Melo; Filipe M de Melo; Diego Mourão-Sá; Priscila Silva; Rodrigo Berzaghi; Carolina C A Herbozo; Jordana Coelho-Dos-Reis; Jorge A Scutti; Clarice S T Origassa; Rosana M Pereira; Luis Juliano; Maria Aparecida Juliano; Adriana K Carmona; Niels O S Câmara; Moriya Tsuji; Luiz R Travassos; Elaine G Rodrigues
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

Review 10.  Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates.

Authors:  Sam Vasilevsky; Milos Stojanov; Gilbert Greub; David Baud
Journal:  Virulence       Date:  2015-11-18       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.